Sophie Sanford

Sophie Sanford is a Senior Scientist at Alchemab Therapeutics Ltd, specializing in Target Deconvolution and Characterisation. Previously, Sophie worked at the UK Dementia Research Institute as a PhD Graduate Student, focusing on innate antiviral immunity and tau aggregation, and authored a thesis that earned the Milo Keynes Prize for 2024. Sophie's contributions extend to leadership roles in diversity and inclusion initiatives and participation in international dialogues on dementia research. Recognized for excellence in presentations and public engagement, Sophie received multiple awards, including the British Neuroscience Association Public Engagement Prize and the UK Dementia Research Institute Engagement Award. Educationally, Sophie holds a PhD in Clinical Neuroscience from the University of Cambridge and a BS in Immunology and Infection from UCL.